- Home
- CLLS vs NLSP Comparison
CLLS vs NLSP Comparison
Compare CLLS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- NLSP
- Stock Information
- Founded
- CLLS 1999
- NLSP 2015
- Country
- CLLS France
- NLSP Switzerland
- Employees
- CLLS N/A
- NLSP N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- NLSP Health Care
- Exchange
- CLLS Nasdaq
- NLSP Nasdaq
- Market Cap
- CLLS 143.4M
- NLSP 12.4M
- IPO Year
- CLLS 2007
- NLSP 2021
- Fundamental
- Price
- CLLS $1.59
- NLSP $2.10
- Analyst Decision
- CLLS Buy
- NLSP
- Analyst Count
- CLLS 1
- NLSP 0
- Target Price
- CLLS $4.00
- NLSP N/A
- AVG Volume (30 Days)
- CLLS 48.2K
- NLSP 275.3K
- Earning Date
- CLLS 08-05-2025
- NLSP 07-22-2025
- Dividend Yield
- CLLS N/A
- NLSP N/A
- EPS Growth
- CLLS N/A
- NLSP N/A
- EPS
- CLLS N/A
- NLSP N/A
- Revenue
- CLLS $54,747,000.00
- NLSP N/A
- Revenue This Year
- CLLS $48.52
- NLSP N/A
- Revenue Next Year
- CLLS $5.17
- NLSP N/A
- P/E Ratio
- CLLS N/A
- NLSP N/A
- Revenue Growth
- CLLS 351.26
- NLSP N/A
- 52 Week Low
- CLLS $1.10
- NLSP $1.30
- 52 Week High
- CLLS $2.43
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- CLLS 56.98
- NLSP 46.61
- Support Level
- CLLS $1.56
- NLSP $2.20
- Resistance Level
- CLLS $1.49
- NLSP $3.08
- Average True Range (ATR)
- CLLS 0.09
- NLSP 0.25
- MACD
- CLLS 0.01
- NLSP -0.06
- Stochastic Oscillator
- CLLS 80.00
- NLSP 8.40
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.